10-Q: Rafael Holdings Reports Wider Q1 Loss Amid Cyclo Merger

Rafael Holdings, Inc. reported a wider net loss in its first fiscal quarter, driven by significantly increased research and development expenses following the acquisition of Cyclo Therapeutics and its pivotal Phase 3 clinical trial for Trappsol Cyclo.

Summary

• Net loss attributable to Rafael Holdings, Inc. increased to $9.8 million for the three months ended October 31, 2025, compared to $9.0 million for the same period in 2024.
• Total revenue grew to $240,000 for the quarter, up from $128,000 in the prior year, primarily due to product revenue from the newly acquired Cyclo.
• Loss from operations significantly widened to $10.1 million, compared to $3.8 million in the previous year, mainly due to a 545% increase in research and development expenses.
• Cash and cash equivalents decreased by $7.2 million to $45.5 million as of October 31, 2025, from $52.8 million on July 31, 2025.
• The company expects its cash balance to be sufficient to meet obligations for at least the next 12 months.
• A material weakness in internal control over financial reporting was identified at the acquired Cyclo subsidiary, related to accruals and expenses.

Sentiment

Score: 4

Explanation: While revenue increased and a key medical device received FDA clearance, the company experienced a significantly wider operating loss and net loss, driven by a substantial increase in R&D expenses for its lead drug candidate. Cash burn from operations also increased, and a material weakness in internal controls at a recently acquired subsidiary was identified. The liquidity position is stated as sufficient for 12 months, but the overall financial performance for the quarter is negative.

Positives

• Total revenue increased by 87.5% to $240,000 for the three months ended October 31, 2025, primarily driven by product revenue from the Cyclo merger.
• Rafael Medical Devices received FDA clearance for its VECTR System on December 11, 2024, for use in minimally invasive ligament or fascia release surgeries.
• The Infusion Technology segment's loss from operations decreased by 89% to $29,000, following an asset sale and licensing agreement.
• The Real Estate segment shifted from a loss of $59,000 to an income of $12,000 from operations, an improvement of $71,000.
• Loss per share improved to $(0.19) from $(0.37) in the prior year, despite a higher net loss, due to a significant increase in weighted average shares outstanding.
• The company successfully settled convertible notes payable with three holders, recognizing a gain of $34,000.

Negatives

• Net loss attributable to Rafael Holdings, Inc. increased by 9% to $9.8 million for the three months ended October 31, 2025, compared to $9.0 million in the prior year.
• Loss from operations significantly widened by 164% to $10.1 million, primarily due to a substantial increase in research and development expenses.
• Research and development expenses in the Healthcare segment surged by 545% to $7.5 million, mainly due to the consolidation of Cyclo's R&D activities.
• Cash and cash equivalents decreased by $7.2 million (14%) to $45.5 million as of October 31, 2025.
• Working capital decreased by $8.9 million (20%) to $36.2 million.
• Net cash used in operating activities more than doubled, increasing by 124% to $6.8 million.
• The company shifted from providing $8.6 million in cash from investing activities in the prior year to using $0.4 million in the current quarter.
• Series C Convertible Notes with an aggregate principal amount of $608,000 are in default as of October 31, 2025.

Risks

• A material weakness in internal control over financial reporting was identified at Cyclo, specifically regarding accruals and expenses, including clinical trial accruals, due to inadequately designed controls.
• There is no assurance that remediation efforts for the material weakness will be effective in the future or that additional material weaknesses will not develop or be identified.
• Future product development for Rafael Medical Devices depends on the success of the VECTR System and the company's ability to identify attractive market opportunities.
• LipoMedix is currently exploring strategic options for its lead candidate, including potential licensing opportunities, collaborations, and investigator-initiated studies, indicating potential uncertainty in its development path.
• The company has curtailed early-stage development efforts, including pre-clinical research at Barer Institute, to reduce spending and focus resources on core assets.
• Cornerstone's current efforts, prospects, and available resources are under review to determine the optimal operational direction, implying potential strategic shifts or resource allocation decisions.
• Foreign currency exchange rate fluctuations could affect revenues and expenses denominated in non-U.S. Dollars, although the net exposure is generally not material.

Future Outlook

The company's primary focus is to complete the development of Trappsol Cyclo through its ongoing pivotal Phase 3 clinical trial, aiming for regulatory approval and market entry. It also plans to expand its investment portfolio through opportunistic and strategic investments in therapeutics addressing high unmet medical needs. The company is evaluating its other holdings to focus resources on core assets and the Trappsol Cyclo development. Future product development for Rafael Medical Devices depends on the success of the VECTR System and identifying attractive market opportunities.

Management Comments

• "Our primary focus is to finish development of Trappsol Cyclo through the completion of its ongoing pivotal Phase 3 clinical trial and bring that product to regulatory approval and market, and to expand its investment portfolio through opportunistic and strategic investments, including in therapeutics, that address high unmet medical needs."
• "We are currently evaluating our other holdings to ensure the future focus of our resources on core assets and specifically the Trappsol Cyclo clinical and development efforts."
• "We expect the balance of cash and cash equivalents to be sufficient to meet our obligations for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q."
• "We do not anticipate paying dividends on our common stock until we achieve sustainable profitability and retain certain minimum cash reserves."

Industry Context

Rafael Holdings operates in the highly capital-intensive biotechnology sector, where significant R&D investment is required for drug development, particularly for rare diseases like Niemann-Pick Disease Type C1. The substantial increase in R&D expenses reflects the typical progression of a biotech company advancing a lead candidate into pivotal Phase 3 trials, a critical and costly stage before potential market approval. The FDA clearance for the VECTR System in medical devices indicates diversification and potential for revenue generation outside of drug development, aligning with a trend of companies seeking multiple growth avenues. The curtailment of early-stage research at Barer Institute and exploration of strategic options for LipoMedix suggest a strategic focus on late-stage assets and a more disciplined approach to R&D spending, common in the industry to conserve capital and prioritize high-potential programs.

Comparison to Industry Standards

• The significant increase in R&D expenses to $7.5 million for the quarter, primarily due to the Phase 3 clinical trial for Trappsol Cyclo, is consistent with industry benchmarks for biotechnology companies advancing a lead candidate into late-stage development. For example, companies like BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, which focus on rare diseases, often incur substantial R&D costs during pivotal trials, sometimes exceeding tens of millions per quarter, reflecting the high cost of patient enrollment, drug manufacturing, and regulatory processes.
• The FDA 510(k) clearance for the VECTR System by Rafael Medical Devices is a positive regulatory milestone, comparable to similar clearances received by medical device companies such as Stryker Corporation or Zimmer Biomet Holdings, Inc. for new surgical instruments, which typically enable market entry and revenue generation in specialized surgical fields.
• The identified material weakness in internal controls at the acquired Cyclo subsidiary, while concerning, is not uncommon in post-merger integrations, especially when combining companies with different operational scales and control environments. Larger pharmaceutical companies like Pfizer or Johnson & Johnson often face similar challenges in integrating acquired entities, requiring robust remediation plans to align internal control frameworks.

Management Changes

Corporate Governance

Legal Proceedings

• The company may from time to time be subject to legal proceedings that arise in the ordinary course of business. It does not expect any of these legal proceedings to have a material adverse effect on its results of operations, cash flows, or financial condition.

Related Party Transactions

• IDT Corporation (a related party through common ownership and management) billed the company approximately $88,000 for services and leased office and parking space, generating approximately $30,000 in rental revenue for the quarter.
• Howard S. Jonas (Chairman of the Board, former CEO) entered into a Standby Purchase Agreement for a $25.0 million rights offering. Related parties of Mr. Jonas purchased approximately $21.0 million of unsubscribed Class B common stock in a private placement. Mr. Jonas has voting power over approximately 51% of the company's combined outstanding capital stock.
• The company invested $500,000 in NINA Medical Ltd., where Howard S. Jonas also holds an indirect investment and serves as the Seed Director.
• Cornerstone is obligated to pay royalties to Altira Capital and Consulting LLC, which is a consolidated subsidiary of the company.

Stakeholder Impact

• Shareholders: Increased net loss and cash burn could negatively impact short-term share price. The significant R&D investment in Trappsol Cyclo represents a long-term value proposition, but also a high-risk, high-reward scenario. The rights offering and private placement by related parties of Howard S. Jonas indicate continued insider support and potential dilution for other shareholders.
• Employees: Management changes (CMO resignation, Cyclo CEO transition to Vice-Chairman) and curtailment of early-stage research at Barer Institute could affect employee morale and job security in certain segments. Stock-based compensation continues to be a component of remuneration.
• Customers: FDA clearance of the VECTR System for Rafael Medical Devices could benefit customers seeking minimally invasive surgical solutions. The asset sale and licensing by Day Three Labs Manufacturing might alter product offerings or availability for its customers.
• Creditors: Cornerstone's Series C Convertible Notes with $608,000 principal are in default, posing a risk to those creditors. The forbearance agreement with a major creditor indicates ongoing debt management.
• Regulatory Authorities: The identified material weakness in internal controls at Cyclo will require close monitoring and successful remediation to ensure compliance and accurate financial reporting.

Next Steps

• Complete the pivotal Phase 3 clinical trial for Trappsol Cyclo.
• Bring Trappsol Cyclo to regulatory approval and market.
• Expand the investment portfolio through opportunistic and strategic investments in therapeutics.
• Evaluate other holdings to focus resources on core assets and Trappsol Cyclo development.
• Explore strategic options for LipoMedix's lead candidate, including potential licensing, collaborations, and investigator-initiated studies.
• Seek partners for Farber programs.
• Develop SHMT through Forme Therapeutics, seeking external investment and partnerships.
• Review Cornerstone's current efforts, prospects, and available resources to determine optimal operational direction.
• Develop future products for Rafael Medical Devices, dependent on the success of the VECTR System and identifying attractive market opportunities.
• Implement a remediation plan for the material weakness in internal control over financial reporting at Cyclo, including integrating vendor/AP management, accrual processes, analytical review, and clinical trial accrual estimation.

Key Dates

Recommendation

Rafael Holdings presents a mixed financial picture. While revenue growth and a significant FDA clearance for a medical device are positive, the substantial increase in net loss and cash burn, driven by critical Phase 3 R&D for Trappsol Cyclo, indicates a high-risk, high-reward biotech investment. The identified material weakness in internal controls at the acquired Cyclo subsidiary adds a layer of operational risk. The company's liquidity is stated as sufficient for 12 months, and insider participation in a recent capital raise shows confidence. However, the current financial performance and operational challenges suggest a "hold" recommendation, awaiting further clarity on the Trappsol Cyclo trial results, successful remediation of internal control weaknesses, and the strategic direction of its diverse portfolio. Investors should monitor these developments closely before making further investment decisions.

Keywords

Biotechnology, Niemann-Pick Disease Type C1, Trappsol Cyclo, Phase 3 Clinical Trial, SEC Filing, Quarterly Report, Healthcare, Medical Devices, VECTR System, FDA Clearance, Cyclo Therapeutics, Financial Results, R&D Expenses, Cash Flow, Internal Controls, Corporate Governance